PR Public relations news

• JELD-WEN Completes Sale of Australasia Business to Platinum Equity

  02-07-2023 23:30
  
  CHARLOTTE, N.C., July 2, 2023 /PRNewswire/ -- JELD-WEN Holding, Inc. (NYSE: JELD), a leading global manufacturer of building products, today announced that it has completed the previously announced sale of its Australasia business to Platinum Equity, a global investment firm. "The closing...
  
  Read more

• Bioheart (02185.HK) anuncia resultado clínico do Iberis-HTN na CIT 2023

  02-07-2023 22:24
  XANGAI, 2 de julho de 2023 /PRNewswire/ -- A Bioheart (02185.HK), juntamente com sua subsidiária holding Angiocare, anuncia o resultado clínico do Iberis-HTN na China Interventional Therapeutics 2023. O Iberis-HTN é um estudo clínico prospectivo, multicêntrico, cego e randomizado para...
  
  Read more

• Bioheart (02185.HK) anuncia sus resultados clínicos para Iberis-HTN en CIT 2023

  02-07-2023 22:21
  SHANGHÁI, 2 de julio de 2023 /PRNewswire/ -- Bioheart (02185.HK), junto con su filial Angiocare anuncia el resultado clínico de Iberis-HTN en China Interventional Therapeutics 2023. Iberis-HTN es un ensayo prospectivo, multicéntrico, ciego, aleatorizado y controlado para evaluar la...
  
  Read more

• Bioheart (02185.HK) annonce les résultats cliniques d'Iberis-HTN lors du salon CIT 2023

  02-07-2023 22:13
  SHANGHAI, 2 juillet 2023 /PRNewswire/ -- Bioheart (02185.HK) et sa filiale Angiocare annoncent les résultats cliniques d'Iberis-HTN lors du salon China Interventional Therapeutics 2023. Iberis-HTN est un essai prospectif, multicentrique, randomisé, contrôlé et mené en aveugle, visant à...
  
  Read more

• Advertisement

• Bioheart (02185.HK) anuncia el resultado clínico de Iberis-HTN en el CIT 2023

  02-07-2023 21:54
  SHANGHÁI, 2 de julio de 2023 /PRNewswire/ -- Bioheart (02185.HK), junto con su subsidiaria de cartera Angiocare, anuncia el resultado clínico de Iberis-HTN en China Interventional Therapeutics 2023. Iberis-HTN es un ensayo controlado prospectivo, multicéntrico, ciego y aleatorizado para...
  
  Read more

• Duke Energy restores power for more than 250,000 customers across Indiana

  02-07-2023 19:05
  
  Approximately 45,000 Indiana customers remain without power as of 12 p.m. today, as multiple waves of storms bring challenging and lengthy repairs. PLAINFIELD, Ind., July 2, 2023 /PRNewswire/ -- Duke Energy has restored power to more than 250,000 Indiana customers, but multiple waves of...
  
  Read more

• Armer Board Introduces the Armer A1 55 4K UHD Interactive Smart Whiteboard

  02-07-2023 19:04
  
  NEW YORK, July 2, 2023 /PRNewswire/ -- Armer Board Introduces the Armer A1 55" 4K UHD Interactive Smart Whiteboard Touch Screen Display, Armer Smart Board Interactive Whiteboard for Workspace, Classroom and Home Office. Armer A1 55'' 4K UHD Touch Screen Interactive Board Introducing our...
  
  Read more

• La exclusiva cuenta Cent de HFM acaba de lanzarse y ya tiene una popularidad increíble

  02-07-2023 17:01
  EBENE, Mauricio, 2 de julio de 2023 /PRNewswire/ -- HFM, marca líder a nivel mundial en el corretaje (anteriormente HotForex), publicó una declaración con respecto a su cuenta Cent (cuenta de centavos), lanzada a principios de este año. En la declaración, la empresa informa que la...
  
  Read more

• Advertisement

• ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DouYu International Holdings Limited Investors to Secure Counsel Before Important Deadline in the Securities Class Action First Filed by the Firm - DOYU

  02-07-2023 17:00
  
  NEW YORK, July 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DouYu International Holdings Limited (NASDAQ: DOYU) between April 30, 2021 and May 9, 2023, both dates inclusive (the "Class Period") of the important...
  
  Read more

• CRL Securities Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Charles River Laboratories International, Inc. (CRL) Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

  02-07-2023 17:00
  
  RADNOR, Pa., July 2, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Charles River Laboratories International, Inc. ("Charles River") (NYSE: CRL). The action charges Charles...
  
  Read more

• Fair Play Menarini International Awards, a edição de 2023 começa com o talk show "The Champions tell their Stories" na Piazza della Signoria, em Florença

  02-07-2023 16:56
  
  FLORENÇA, Itália, 2 de julho de 2023 /PRNewswire/ -- A contagem regressiva começou para a edição XXVII do Fair Play Menarini International Awards. Amanhã, segunda-feira, dia 3 de julho, a edição 2023 do evento, dedicada aos valores esportivos de ética, fair play e respeito, começará...
  
  Read more

• ROSEN, A LEADING LAW FIRM, Encourages SentinelOne, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - S

  02-07-2023 16:30
  
  NEW YORK, July 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SentinelOne, Inc. (NYSE: S) between June 1, 2022 and June 1, 2023, both dates inclusive (the "Class Period"), of the important August 7, 2023 lead plaintiff...
  
  Read more

• Universy Invest Expands Account Offerings for Enhanced Benefits

  02-07-2023 16:22
  SOUTHAMPTON, England, July 2, 2023 /PRNewswire/ -- As financial trading continues to surge in popularity and enter mainstream channels, market participants are particularly seeking platforms that provide them with enhanced trading facilities and a wide array of account options. As a...
  
  Read more

• First Invest Capital Introduces an Efficient and Secure Verification System

  02-07-2023 15:33
  SOUTHAMPTON, England, July 2, 2023 /PRNewswire/ -- As financial trading reaches new levels of conformity and adoption, the need for superior security and verification systems has also skyrocketed. Such a framework ensures that a reliable trading environment is cultivated. In this regard,...
  
  Read more

• Wayfinder Family Services Appoints Jay Allen as President and Chief Executive Officer

  02-07-2023 15:17
  
  LOS ANGELES, July 2, 2023 /PRNewswire/ -- Wayfinder Family Services' board of directors has appointed Jay Allen as president and chief executive officer of the organization. Allen will assume the CEO role in addition to his current duties as president. Allen will lead Wayfinder Family...
  
  Read more

• A Strategic Acquisition - Mango Group LLC Acquires Fxonic, a Leading Online Broker

  02-07-2023 15:08
  KINGSTOWN, St. Vincent and the Grenadines, July 2, 2023 /PRNewswire/ -- In recent years, the online trading space has experienced a tremendous surge in popularity, with more and more individuals leaping into this domain to diversify their income streams. Naturally, numerous trading...
  
  Read more

• Fair Play Menarini International Awards, the 2023 edition starts with the talk show "The Champions tell their Stories" in Piazza della Signoria, Florence

  02-07-2023 14:30
  
  FLORENCE, Italy, July 2, 2023 /PRNewswire/ -- The countdown has begun to the XXVII edition of the Fair Play Menarini International Awards. Tomorrow, Monday, July 3rd, the 2023 edition of the event, dedicated to the sporting values of ethics, fair play and respect, will officially begin in...
  
  Read more

• Global Times: Popular history book unravels complicated history of exchanges between Han Dynasty, Xiongnu tribe

  02-07-2023 11:59
  XINJIANG, China , July 2, 2023 /PRNewswire/ -- Born in Urumqi, Northwest China's Xinjiang Uygur Autonomous Region, writer Li Dong has long been enchanted with the historical culture of his birthplace. The region was once a thoroughfare for the ancient Silk Road, a time when it was...
  
  Read more

• Lifera y CENTOGENE inician una colaboración estratégica, formando una empresa conjunta en Arabia Saudita para aumentar el acceso a importantes pruebas multiómicas basadas en datos

  02-07-2023 11:00
  La empresa conjunta combina el liderazgo global de CENTOGENE en multiómica con el conocimiento local de Lifera, una empresa biofarmacéutica de propiedad absoluta del Fondo de Inversión Pública (PIF) con sede en Riad. La empresa conjunta se enfoca en ofrecer servicios de pruebas...
  
  Read more

• Lifera und CENTOGENE gehen strategische Zusammenarbeit ein - Gründung eines saudi-arabischen Joint Ventures zur Verbesserung des Zugangs zu führenden datengesteuerten multiomischen Tests

  02-07-2023 11:00
  Joint Venture (JV) kombiniert die globale Führungsrolle von CENTOGENE im Bereich der Multiomik mit den lokalen Kenntnissen von Lifera, einem biopharmazeutischen Unternehmen, das sich zu 100 % im Besitz des Public Investment Fund (PIF) mit Sitz in Riad befindet. JV konzentriert sich...
  
  Read more

• Lifera et CENTOGENE créent une coentreprise en Arabie Saoudite pour améliorer l'accès aux principaux tests multiomiques basés sur les données

  02-07-2023 11:00
  La coentreprise associe le leadership mondial de CENTOGENE dans le domaine de la multiomique à la vision locale de Lifera, une société biopharmaceutique entièrement détenue par le Fonds d'investissement public (PIF) basé à Riyad. La coentreprise se concentre sur la fourniture de services...
  
  Read more

• Lifera e CENTOGENE firmam colaboração estratégica, formando uma joint venture na Arábia Saudita para aumentar o acesso aos principais testes multiômicos baseados em dados

  02-07-2023 11:00
  A Joint Venture (JV) combina a liderança global da CENTOGENE em multiômica com a visão local da Lifera, uma empresa biofarmacêutica de propriedade integral do Fundo de Investimento Público (Public Investment Fund, PIF), com sede em Riade. A JV se concentra no fornecimento de serviços de...
  
  Read more

• Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

  02-07-2023 11:00
  Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based in Riyadh. JV focuses on providing state-of-the-art multiomic testing services to patients, health...
  
  Read more

• Colaboración estratégica entre Lifera and CENTOGENE, con la creación de una empresa conjunta

  02-07-2023 11:00
  - Colaboración estratégica entre Lifera and CENTOGENE – Creación de una empresa conjunta en Arabia Saudí para ampliar el acceso a las principales pruebas multiómicas basadas en datos La empresa conjunta (JV) combina el liderazgo mundial de CENTOGENE en multiómica con el conocimiento local...
  
  Read more

• THE JUSTICE RUTH BADER GINSBURG WOMAN OF LEADERSHIP AWARD BESTOWED UPON BARBRA STREISAND

  02-07-2023 03:37
  
  The prestigious award was presented to the Emmy, Grammy, Oscar and Tony Award-winning icon by the Honorable Justice Sonia Sotomayor and Dwight D. Opperman Foundation Chair Julie Opperman in a private ceremony LOS ANGELES, July 1, 2023 /PRNewswire/ -- BARBRA STREISAND received The Justice...
  
  Read more

• SystImmune, Inc. Announces FDA Clearance of IND Application for BL-B01D1, a Bi-specific Antibody Drug Conjugate Targeting EGFR and HER3, Enabling Initiation of Phase 1 Clinical Trials in the U.S. for Metastatic or Unresectable Non-Small Cell Lung Cancer

  02-07-2023 03:00
  
  REDMOND, Wash., July 1, 2023 /PRNewswire/ -- SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of BL-B01D1 in the Investigational New Drug...
  
  Read more

• SystImmune, Inc. Announces FDA Clearance of IND Application for BL-B01D1, a Bi-specific Antibody Drug Conjugate Targeting EGFR and HER3, Enabling Initiation of Phase 1 Clinical Trials for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Can

  02-07-2023 03:00
  
  REDMOND, Wash., July 1, 2023 /PRNewswire/ -- SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of BL-B01D1 in the Investigational New Drug...
  
  Read more

Follow @P_and_R_News on Twitter!